AlloMEK Therapeutics Overview
- Year Founded
-
2011
- Status
-
Acquired/Merged
- Latest Deal Type
-
M&A
- Latest Deal Amount
-
$5.67M
AlloMEK Therapeutics General Information
Description
Developer of targeted therapeutics intended to treat rare and debilitating diseases. The company's therapeutics include kinase inhibitors that improve the biopharmaceutical properties of previous inhibitors and can be used as a single agent and in combination with other treatment options, enabling physicians to provide an improved clinical response for unusual illnesses.
Contact Information
Website
www.allomek.comCorporate Office
- 4 Research Drive
- Woodbridge, CT 06525
- United States
Corporate Office
- 4 Research Drive
- Woodbridge, CT 06525
- United States
AlloMEK Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 7. Merger/Acquisition | 11-Oct-2022 | $5.67M | Completed | Generating Revenue | ||
| 6. Later Stage VC | 10-Feb-2020 | Completed | Generating Revenue | |||
| 5. Accelerator/Incubator | 02-Feb-2018 | Completed | Generating Revenue | |||
| 4. Accelerator/Incubator | 01-Jan-2016 | Completed | Generating Revenue | |||
| 3. Seed Round | 13-Mar-2015 | Completed | Generating Revenue | |||
| 2. Seed Round | 22-Apr-2013 | $220K | $370K | Completed | Startup | |
| 1. Seed Round | 21-Feb-2011 | $150K | $150K | Completed | Startup |
AlloMEK Therapeutics Patents
AlloMEK Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| ES-2534358-T3 | Innovative mek inhibitors useful in the treatment of diseases | Active | 13-Oct-2009 | ||
| US-9034861-B2 | Mek inhibitors useful in the treatment of diseases | Active | 13-Oct-2009 | ||
| US-20150250762-A1 | Novel mek inhibitors for treating cardiomyopathies and related conditions | Inactive | 13-Oct-2009 | ||
| JP-2013507453-A | Novel mek inhibitors useful for the treatment of diseases | Active | 13-Oct-2009 | ||
| JP-5892612-B2 | Novel mek inhibitors useful for the treatment of diseases | Active | 13-Oct-2009 | C07D291/08 |
AlloMEK Therapeutics Former Investors (5)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Accelerator for Biosciences in Connecticut | Accelerator/Incubator | |||
| Connecticut Innovations | Venture Capital | Minority | ||
| Fundación Andrés Marcio | Not-For-Profit Venture Capital | Minority | ||
| Angel (individual) | Minority | |||
| University of Connecticut Technology Incubation Program | Accelerator/Incubator |
AlloMEK Therapeutics FAQs
-
When was AlloMEK Therapeutics founded?
AlloMEK Therapeutics was founded in 2011.
-
Where is AlloMEK Therapeutics headquartered?
AlloMEK Therapeutics is headquartered in Woodbridge, CT.
-
What industry is AlloMEK Therapeutics in?
AlloMEK Therapeutics’s primary industry is Biotechnology.
-
Is AlloMEK Therapeutics a private or public company?
AlloMEK Therapeutics is a Private company.
-
What is the current valuation of AlloMEK Therapeutics?
The current valuation of AlloMEK Therapeutics is .
-
What is AlloMEK Therapeutics’s current revenue?
The current revenue for AlloMEK Therapeutics is .
-
How much funding has AlloMEK Therapeutics raised over time?
AlloMEK Therapeutics has raised $1.73M.
-
Who are AlloMEK Therapeutics’s investors?
Accelerator for Biosciences in Connecticut, Connecticut Innovations, Fundación Andrés Marcio, , and University of Connecticut Technology Incubation Program have invested in AlloMEK Therapeutics.
-
When was AlloMEK Therapeutics acquired?
AlloMEK Therapeutics was acquired on 11-Oct-2022.
-
Who acquired AlloMEK Therapeutics?
AlloMEK Therapeutics was acquired by Pasithea Therapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process